Read More

Enlivex Receives Israeli Ministry Of Health Approval For The Initiation Of A Phase I/II Trial Evaluating Allocetra Alone And In Combination With A PD1 Checkpoint Inhibitor In Patients With Advanced Solid Tumors

Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined with PD1

ENLV